Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2001

View Archived Issues

HIV vaccine candidate evaluated in phase I trials

Lundbeck's psychopharmacological drug pipeline

Neurological drugs in Lundbeck's pipeline

Analysis of study results with topiramate in diabetic neuropathic pain

Human testing of injectable urethral bulking agent in progress

Organon plans to continue development of the Ampakine Org-24448

Novo Nordisk's rapid-acting insulin analogue now available in U.S.

More flexible and personalized therapy now possible with NeoRecormon

TAK-083 highly effective in the laboratory and in animals against H. pylori

Free I2 as an effective oxidant in human sperm

ATLAS study: sequence of events in heart failure progression and protective effects of lisinopril

Allovectin-7 phase III registration trial in metastatic melanoma now fully enrolled

Longer acting treatment for anemia in chronic renal failure cleared for U.S. launch

Amgen elects not to develop Guilford's neuroimmunophilin ligands

Muscarinic receptor binding profile of YM-905 correlated with pharmacological activity

Tiagabine as a potential treatment option for overactive bladder

Taxanes with potent antitumor activity reported by Florida State

New antimycobacterial compounds from Genzyme interfere with cell wall biosynthesis

Bayer and Millennium announce identification of 140 disease-relevant drug targets

Nippon Kayaku prepares new agents for use in photochemical therapy of tumors

Pharmos expands pivotal phase III trial of dexanabinol into U.K.

First evidence that overexpression of dopamine D2 receptor reduces alcohol intake

Erythromycin derivatives identified by Hokuriku active against H. pylori

Two series of factor Xa inhibitors disclosed recently by Cor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...